Neuren Pharmaceuticals Limited (NURPF)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 273.4k | -- | -- |
Ms. Lauren Frazer C.A. | CFO & Company Secretary | -- | -- | -- |
Mr. Lawrence Glass BA (Biology) | Chief Science Officer | -- | -- | -- |
Mr. Gerry Zhao | Vice President of Corporate Development | -- | -- | -- |
Dr. Liza A. Squires M.D. | Chief Medical Officer | -- | -- | -- |
Neuren Pharmaceuticals Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Corporate Governance
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available